Overview

Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection

Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Endoscopic Injection Sclerotherapy vs N-butyl-2-cyanoacrylate Injection
Phase:
Phase 3
Details
Lead Sponsor:
Sherief Abd-Elsalam
Treatments:
Ethanolamine oleate